Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients

BMC Microbiology

Volumn 12, Issue , 2012, Pages

  Mello, Francisco C A ^a   Lago, Bárbara V ^a   Lewis Ximenez, Lia L ^a   Fernandes, Carlos A ^b   Gomes, Selma A ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Laboratório Central de Saúde Pública Noel Nutels LACEN RJ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; VIRUS DNA;

ANTIVIRAL THERAPY; ARTICLE; BRAZIL; CONTROLLED STUDY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; PHYLOGENY; PYROSEQUENCING; SERUM; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS ISOLATION; WILD TYPE; ANTIVIRAL RESISTANCE; BLOOD; DNA SEQUENCE; DRUG EFFECTS; GENETICS; MUTATION; PROCEDURES; VIROLOGY;

HEPATITIS B VIRUS;

DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA;

EID: 84861834523     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-12-96     Document Type: Article

References (28)

1. Yuen LK, Locarnini SA: Genetic variability of hepatitis B virus and response to antiviral treatments: searching for a bigger picture. J Hepatol 2009, 50:445-448.
2. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trepo C, Zoulim F: Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000, 32: 1078-1088.
3. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001, 34:785-791. (Pubitemid 32928004)
4. Shamliyan TA, Johnson JR, MacDonald R, Shaukat A, Yuan JM, Kane RL, Wilt TJ: Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med 2011, 26:326-339.
5. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999, 341:1256-1263. (Pubitemid 29489740)
6. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L: Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003, 36:687-696. (Pubitemid 36337972)
7. Zoulim F, Locarnini S: Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009, 137:1593-1608. e1591-1592.
8. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27:1670-1677. (Pubitemid 28264693)
9. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ: Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996, 24:711-713. (Pubitemid 26296020)
10. Allen MI, Gauthier J, DesLauriers M, Bourne EJ, Carrick KM, Baldanti F, Ross LL, Lutz MW, Condreay LD: Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999, 37:3338-3347. (Pubitemid 29455230)
11. Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Koida I, Arase Y, Saitoh S, et al: Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998, 27:1711-1716. (Pubitemid 28264699)
12. Jardi R, Buti M, Rodriguez-Frias F, Cotrina M, Costa X, Pascual C, Esteban R, Guardia J: Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J Virol Methods 1999, 83:181-187. (Pubitemid 29528556)
13. Cane PA, Cook P, Ratcliffe D, Mutimer D, Pillay D: Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus. Antimicrob Agents Chemother 1999, 43:1600-1608. (Pubitemid 29331235)
14. Kim HS, Han KH, Ahn SH, Kim EO, Chang HY, Moon MS, Chung HJ, Yoo W, Kim SO, Hong SP: Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther 2005, 10:441-449. (Pubitemid 41151022)
15. Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, Rossau R: Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000, 38:702-707. (Pubitemid 30082666)
16. Tran N, Berne R, Chann R, Gauthier M, Martin D, Armand MA, Ollivet A, Teo CG, Ijaz S, Flichman D, et al: European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes. J Clin Microbiol 2006, 44: 2792-2800. (Pubitemid 44228573)
17. Wang RS, Zhang H, Zhu YF, Han B, Yang ZJ: Detection of YMDD mutants using universal template real-time PCR. World J Gastroenterol 2006, 12:1308-1311.
18. Malmstrom S, Hannoun C, Lindh M: Mutation analysis of lamivudine resistant hepatitis B virus strains by TaqMan PCR. J Virol Methods 2007, 143:147-152. (Pubitemid 46963385)
19. Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR: Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol 2009, 83:1718-1726.
20. Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, Wang C, Holmes SP, Babrzadeh F, Gharizadeh B, Hanczaruk B, et al: Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 2009, 199:1275-1285.
21. Mello FCA, Fernandes CA, Gomes SA: Antiviral therapy against chronic hepatitis B in Brazil: High rates of lamivudine resistance mutations and correlation with HBV genotypes. Mem Inst Oswaldo Cruz 2012, 107: 317-325.
22. Moraes MT, Niel C, Gomes SA: A polymerase chain reaction-based assay to identify genotype F of hepatitis B virus. Braz J Med Biol Res 1999, 32:45-49. (Pubitemid 129591670)
23. Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994, 22:4673-4680. (Pubitemid 24354800)
24. Tamura K, Dudley J, Nei M, Kumar S: MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24:1596-1599. (Pubitemid 47236692)
25. Sucupira MV, Mello FC, Santos EA, Niel C, Rolla VC, Arabe J, Gomes SA: Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations. Mem Inst Oswaldo Cruz 2006, 101:655-660. (Pubitemid 44555612)
26. Shaw T, Bartholomeusz A, Locarnini S: HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006, 44:593-606. (Pubitemid 43227885)
27. Ijaz S, Arnold C, Dervisevic S, Mechurova J, Tatman N, Tedder RS, Naoumov NV: Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. J Med Virol 2008, 80:1160-1170. (Pubitemid 351705994)
28. Lindstrom A, Odeberg J, Albert J: Pyrosequencing for detection of lamivudine-resistant hepatitis B virus. J Clin Microbiol 2004, 42:4788-4795. (Pubitemid 39362404)